CoChat

Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study

Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., Milicevic, Z. · 2012 · Diabetic Medicine
Cited by 102

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 29, 1260–1267 (2012) Aims Evaluate dose‐dependent effects of once‐weekly dulaglutide, a glucagon‐like peptide‐1 analogue, on glycaemic control in patients with Type 2 diabetes treated with lifestyle measures with or without previous metformin. Methods This 12‐week, double‐blind, placebo‐controlled, dose–response trial randomized 167 patients who were anti‐hyperglycaemic medication‐naïve or had discontinued metformin monotherapy [mean baseline HbA 1c 59 ± 8 to 61 ± 8 mmol/mol (7.6 ± 0.7 to 7.8 ± 0.8%)] to once‐weekly injections of placebo or dulaglutide (0.1, 0.5, 1.0 or 1.5 mg). Results A significant dose‐dependent reduction in HbA 1c (least squares mean ± se) was observed across doses (P < 0.001). HbA 1c reductions in the 0.5, 1.0 and 1.5 mg dulaglutide groups were greater than in the placebo group [−10 ± 1, −11 ± 1 and −11 ± 1 vs. 0 ± 1 mmol/mol (−0.9 ± 0.1, −1.0 ± 0.1 and −1.0 ± 0.1 vs. 0.0 ± 0.1%), respectively, all P < 0.001]. Dose‐dependent reductions in fasting plasma glucose were also observed [least squares mean difference (95% CI) ranging from −0.43 (−1.06 to 0.19) mmol/l for dulaglutide 0.1 mg to −1.87 (−2.56 to −1.19) mmol/l for dulaglutide 1.5 mg, P < 0.001]. Dose‐dependent weight loss was demonstrated across doses (P = 0.009), but none of the groups were different from placebo. The most common adverse events were nausea and diarrhoea. Conclusions The observed dulaglutide dose‐dependent reduction in HbA 1c and its acceptable safety profile support further clinical development for treatment of Type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03745.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 10

  1. 10.1016/j.pharmthera.2009.06.002 · DOI · Paper page
  2. 10.2337/dc06-2593 · DOI · Paper page
  3. 10.1111/j.1463-1326.2009.01187.x · DOI · Paper page
  4. 10.2337/dc06-2375 · DOI · Paper page
  5. 10.1210/jc.2008-1518 · DOI · Paper page
  6. 10.2337/dc09-0366 · DOI · Paper page
  7. 10.1002/dmrr.1080 · DOI · Paper page
  8. 10.2337/diacare.27.6.1335 · DOI · Paper page
  9. 10.1111/j.1463-1326.2011.01366.x · DOI · Paper page
  10. Bastyr EJ, 2009, High incidence of elevated lipase and amylase in Type 2 diabetes patients (T2DM), Pancreas, 38, 980

Cited by

See all 102

Metadata

Authors
Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., & Milicevic, Z.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2012-09-18
Volume
29
Issue
10
Pages
1260-1267
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1562038277
Cited by
102
References
8
FWCI
8.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1464-5491.2012.03745.x
The paper
Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., & Milicevic, Z. (2012). Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2012.03745.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.